Hillevax

IPO

XOMA Royalty – A biotech royalty aggregator

Public · Boston, United States · Founded 2021 · $136.3M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$136.3M
Last Round
$135.0M Series DSep 2021
Rounds
2
Type
Public

About

HilleVax is a clinical-stage biopharmaceutical company focused on developing vaccines. Lead program HIL-214 is a bivalent VLP vaccine candidate for moderate-to-severe acute gastroenteritis from norovirus in infants. Founded 2021, HQ Boston. Raised $136M. Phase 2b trial showed limited efficacy 2024. Website now redirects to XOMA Royalty.

Summary

Hillevax is a Biotech company based in Boston, United States, founded in 2021. It has raised $136.3M in total across 2 rounds, most recently a $135.0M Series D round in Sep 2021. Investors include Frazier Healthcare, Takeda (JP) and Lightspeed Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOMay 2022
$230.0M

Sign up to see all 4 rounds

Acquisition through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Hillevax on Indexed.vc
<a href="https://indexed.vc/companies/hillevax"><img src="https://indexed.vc/api/badge/company/hillevax" alt="Hillevax on Indexed.vc" width="260" height="76" /></a>